Rejuvenating aging liver cells halves an Alzheimer's-linked protein in rats
An experimental drug restored aging liver cells in old rats, cutting amyloid beta by half and returning LDL cholesterol to youthful levels within two weeks.
Summary
The liver may be an unexpected target for fighting age-related disease. Researchers at the Keck School of Medicine of USC treated older rats with an experimental drug called cinaciguat for two weeks. The treatment reversed signs of aging in specialized liver cells that filter the blood. Levels of amyloid beta, a protein linked to Alzheimer's disease, dropped by half, and LDL cholesterol returned to levels seen in young animals. The team also uncovered a previously unknown way that liver cells communicate with each other to clear harmful substances from the bloodstream. Because the approach works through the liver, it sidesteps the blood-brain barrier, a major obstacle for brain-targeted drugs. The findings, published in the Journal of Biological Chemistry, point toward a new strategy for reducing the risk of both Alzheimer's disease and atherosclerosis. However, the work so far has been done only in rats, and human studies are needed before anyone can say whether similar benefits would occur in people.
Detailed Summary
Alzheimer's disease and heart disease are two of the most serious conditions of aging, and treatments for both remain limited. A new rat study from the Keck School of Medicine of USC suggests that a single organ, the liver, may offer a shared route to addressing them.
Researchers treated older rats with cinaciguat, an experimental drug, for two weeks. The treatment reversed key signs of aging in specialized liver cells that filter blood. Amyloid beta, the protein associated with Alzheimer's disease, fell by half. LDL cholesterol, the so-called bad cholesterol that drives atherosclerosis, returned to the levels seen in younger animals. The study, published in the Journal of Biological Chemistry, also revealed a previously unknown communication system among liver cells that helps them remove harmful substances from the blood.
The insight is notable because efforts to treat Alzheimer's directly in the brain have failed in an estimated 98% of clinical trials. The blood-brain barrier makes delivering drugs to the brain especially difficult. Restoring the liver's natural cleaning function sidesteps that barrier entirely. The authors also note that the results fit epidemiological evidence that age is a major risk factor for both Alzheimer's and atherosclerosis, and that liver damage raises Alzheimer's risk.
For readers, the practical message is mostly conceptual for now. It reinforces the idea that organ health outside the brain, particularly liver function, may influence brain aging and cardiovascular risk. Nothing here supports taking any drug or supplement, as cinaciguat is experimental and has not been tested for this purpose in people.
The caveats are significant. The results come from rats, and the corresponding author stressed that more translational work is required. It remains unknown whether the effects last beyond two weeks, whether they are safe over time, or whether amyloid reduction in the blood would translate into lower Alzheimer's risk in humans.
Key Findings
- Two weeks of cinaciguat reversed aging features in specialized liver cells of older rats.
- Amyloid beta, an Alzheimer's-linked protein, dropped by half after treatment.
- LDL cholesterol returned to levels seen in younger rats, suggesting relevance to atherosclerosis.
- Researchers identified a previously unknown communication pathway among liver cells that aids blood clearance.
- Results are rat-only; human translation and long-term safety remain untested.
Methodology
This is a university press release summarized in a science news report on a preclinical study in older rats, published in the Journal of Biological Chemistry. The source is credible, but the coverage is institutional and the article is truncated. Evidence is animal-based and has not been tested in humans.
Study Limitations
Findings come from a small-scale rodent study with a short two-week treatment, and the article does not give sample sizes, durability, or safety data. It is unclear whether lowering blood amyloid beta reduces brain pathology or dementia risk. Consult the original Journal of Biological Chemistry paper for methods and effect sizes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: